WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Year in Review 2024 - Key Trials and Progress in SCLC Treatment

Oncology 2024 Year in Review

N. Seetharamu

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

Adjuvant & Neoadjuvant Therapy in Early NSCLC With Actionable Genomi…

Fox Chase Cancer Center

J. Reuss

WCLC 2024 Insights: Adjuvant vs. Neoadjuvant vs. Peri-Operative Ther…

Insights from 2024 WCLC

J. Von Der Thusen

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

1L IO Advances in ES-SCLC Treatment

Fox Chase Cancer Center

A. Chiang

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

Year in Review 2024 - Top Clinical Trials in Neuro-Oncology

Oncology 2024 Year in Review

S. Bagley

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

Year in Review 2024 - Small Cell Lung Cancer

Nebraska Oncology Society

J. Murray

Unresectable Stage 3 NSCLC: Patient Selection and Treatment Options

Fox Chase Cancer Center

C. Aggarwal